Page 2149 - Hematology_ Basic Principles and Practice ( PDFDrive )

Chapter 126 Molecular Basis of Blood Coagulation 1905.e5

201. Harpel PC: Alpha2-plasmin inhibitor and alpha2-macroglobulin- 225. Hancock WW, Grey ST, Hau L, et al: Binding of activated protein
plasmin complexes in plasma. Quantitation by an enzyme-linked C to a specific receptor on human mononuclear phagocytes inhibits
differential antibody immunosorbent assay. J Clin Invest 68:46, 1981. intracellular calcium signaling and monocyte-dependent proliferative
202. Mitchell L, Piovella F, Ofosu F, et al: Alpha-2-macroglobulin may responses. Transplantation 60:1525, 1995.
provide protection from thromboembolic events in antithrombin III- 226. Tuszynski GP, Bevacqua SJ, Schmaier AH, et al: Factor XI antigen and
deficient children. Blood 78:2299, 1991. activity in human platelets. Blood 59:1148, 1982.
203. Abbink JJ, Nuijens JH, Eerenberg AJ, et al: Quantification of func- 227. Bagdasarian A, Colman RW: Subcellula localization and purification of
tional and inactivated alpha 2-macroglobulin in sepsis. Thromb Haemost platelet alpha1-antitrypsin. Blood 51:139, 1978.
65:32, 1991. 228. Schwarz HP, Heeb MJ, Wencel-Drake JD, et al: Identification
204. Huang SS, O’Grady P, Huang JS: Human transforming growth factor and quantitation of protein S in human platelets. Blood 66:1452,
beta.alpha 2-macroglobulin complex is a latent form of transforming 1985.
growth factor beta. J Biol Chem 263:1535, 1988. 229. Novotny WF, Girard TJ, Miletich JP, et al: Platelets secrete a coagula-
205. Borth W, Luger TA: Identification of alpha 2-macroglobulin as a tion inhibitor functionally and antigenically similar to the lipoprotein
cytokine binding plasma protein. Binding of interleukin-1 beta to “F” associated coagulation inhibitor. Blood 72:2020, 1988.
alpha 2-macroglobulin. J Biol Chem 264:5818, 1989. 230. McDonagh J, McDonagh RP, Jr, Delage JM, et al: Factor XIII in
206. Matsuda T, Hirano T, Nagasawa S, et al: Identification of alpha human plasma and platelets. J Clin Invest 48:940, 1969.
2-macroglobulin as a carrier protein for IL-6. J Immunol 142:148, 231. Holt JC, Niewiaroswski S: Secretion of plasminogen by washed human
1989. platelets. Circulation 62:342, 1980.
207. Dennis PA, Saksela O, Harpel P, et al: Alpha 2-macroglobulin is a 232. Plow EF, Collen D: The presence and release of alpha 2-antiplasmin
binding protein for basic fibroblast growth factor. J Biol Chem 264:7210, from human platelets. Blood 58:1069, 1981.
1989. 233. Erickson LA, Hekman CM, Loskutoff DJ: The primary plasminogen-
208. Wollenberg GK, LaMarre J, Rosendal S, et al: Binding of tumor activator inhibitors in endothelial cells, platelets, serum, and plasma are
necrosis factor alpha to activated forms of human plasma alpha 2 immunologically related. Proc Natl Acad Sci USA 82:8710, 1985.
macroglobulin. Am J Pathol 138:265, 1991. 234. Kruithof EK, Tran-Thang C, Bachmann F: Studies on the release of a
209. Legres LG, Pochon F, Barray M, et al: Evidence for the binding of a plasminogen activator inhibitor by human platelets. Thromb Haemost
biologically active interleukin-2 to human alpha 2-macroglobulin. J 55:201, 1986.
Biol Chem 270:8381, 1995. 235. Brass LF: Thrombin and platelet activation. Chest 124:18S, 2003.
210. Kovacs DM: alpha2-macroglobulin in late-onset Alzheimer’s disease. 236. White JG: Views of the platelet cytoskeleton at rest and at work. Ann
Exp Gerontol 35:473, 2000. N Y Acad Sci 509:156, 1987.
211. McGeer PL, McGeer EG: Polymorphisms in inflammatory genes and 237. Hartwig JH: Platelet morphology. In Loscalzo J, Schafer AI, editors:
the risk of Alzheimer disease. Arch Neurol 58:1790, 2001. Thrombosis and hemorrhage, Baltimore, 1998, Williams & Wilkins, p
212. Zappia M, Cittadella R, Manna I, et al: Genetic association of alpha2- 207.
macroglobulin polymorphisms with AD in southern Italy. Neurology 238. Parise LV, Boudignon-Proudhon C, Keely PJ, et al: Platelets in hemo-
59:756, 2002. statis. In Foersten J, Lukens J, Paraskevas F, et al, editors: Wintrobe’s
213. Kruger U: [Chronic obstructive lung disease and alpha-2-macroglobulin clinical hematology, Baltimore, 1999, Williams & Wilkins, p 661.
deficiency in serum–case report]. Pneumologie 47:531, 1993. 239. Nurden AT: Human platelet membrane glycoproteins. In Bloom AL,
214. Kanoh Y, Ohtani H, Koshiba K: [Studies on alpha 2 macroglobulin Forbes CD, Thomas DP, et al, editors: Hemostasis and thrombosis, New
deficiency in association with cancer metastasis.]. Nihon Rinsho Meneki York, 1994, Churchill Livingstone, p 115.
Gakkai Kaishi 20:30, 1997. 240. Bevers EM, Comfurius P, Zwaal RF: Changes in membrane phos-
215. Umans L, Serneels L, Overbergh L, et al: Targeted inactivation of the pholipid distribution during platelet activation. Biochim Biophys Acta
mouse alpha 2-macroglobulin gene. J Biol Chem 270:19778, 1995. 736:57, 1983.
216. Webb DJ, Wen J, Lysiak JJ, et al: Murine alpha-macroglobulins 241. Bouchard BA, Catcher CS, Thrash BR, et al: Effector cell protease
demonstrate divergent activities as neutralizers of transforming growth receptor-1, a platelet activation-dependent membrane protein, regulates
factor-beta and as inducers of nitric oxide synthesis. A possible mecha- prothrombinase-catalyzed thrombin generation. J Biol Chem 272:9244,
nism for the endotoxin insensitivity of the alpha2-macroglobulin gene 1997.
knock-out mouse. J Biol Chem 271:24982, 1996. 242. Altieri DC, Edgington TS: Sequential receptor cascade for coagula-
217. Griendling KK, Alexander RW: Endothelial control of the cardiovascu- tion proteins on monocytes. Constitutive biosynthesis and functional
lar system: recent advances. FASEB J 10:283, 1996. prothrombinase activity of a membrane form of factor V/Va. J Biol
218. Rodgers GM: Endothelium and the regulation of hemostasis. In Lee Chem 264:2969, 1989.
GR, Lickins J, Paraskevas F, et al, editors: Wintrobe’s clinical hematology, 243. Altieri DC, Edgington TS: Identification of effector cell protease
Baltimore, 1999, Williams & Wilkins, p 765. receptor-1. A leukocyte-distributed receptor for the serine protease
219. Colman RW, Marder VJ, Salzman EW, et al: Overview of hemostasis. factor Xa. J Immunol 145:246, 1990.
In Colman RW, Hirsh J, Marder VJ, et al, editors: Hemostasis and 244. Altieri DC, Stamnes SJ: Protease-dependent T cell activation: ligation
thrombosis: Basic principles and clinical practice, Philadelphia, 1994, of effector cell protease receptor-1 (EPR-1) stimulates lymphocyte
Lippincott, p 3. proliferation. Cell Immunol 155:372, 1994.
220. Makrides SC, Ryan US: Overview of the endothelium. In Loscalzo 245. Blomback B: Fibrinogen: evolution of the structure-function concept.
J, Schafer AI, editors: Thrombosis and hemorrhage, Baltimore, 1998, Keynote address at fibrinogen 2000 congress. Ann N Y Acad Sci 936:1,
Williams & Wilkins, p 295. 2001.
221. Ware AG, Seegers WH: Two-stage procedure for the quantitative 246. Doolittle RF, Yang Z, Mochalkin I: Crystal structure studies on fibrino-
determination of prothrombin concentration. Am J Clin Pathol 19:471, gen and fibrin. Ann N Y Acad Sci 936:31, 2001.
1949. 247. Bailey K, Bettelheim FR, Lorand L, et al: Action of thrombin in the
222. Weiss HJ, Turitto VT, Baumgartner HR: Role of shear rate and platelets clotting of fibrinogen. Nature 167:233, 1951.
in promoting fibrin formation on rabbit subendothelium. Studies 248. Blomback B: Studies on the action of thrombotic enzymes on bovine
utilizing patients with quantitative and qualitative platelet defects. J fibrinogen as measured by N-terminal analysis. Arkiv Kemi 12:321,
Clin Invest 78:1072, 1986. 1958.
223. Bevilacqua MP, Pober JS, Majeau GR, et al: Interleukin 1 (IL-1) 249. Hirose S, Oda K, Ikehara Y: Biosynthesis, assembly and secretion of
induces biosynthesis and cell surface expression of procoagulant activity fibrinogen in cultured rat hepatocytes. Biochem J 251:373, 1988.
in human vascular endothelial cells. J Exp Med 160:618, 1984. 250. Lee SY, Lee KP, Lim JW: Identification and biosynthesis of fibrinogen
224. Esmon CT: Structure and functions of the endothelial cell protein C in human uterine cervix carcinoma cells. Thromb Haemost 75:466,
receptor. Crit Care Med 32:S298, 2004. 1996.